Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03517722 · ClinicalTrials.gov registry record · Phase 3
A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
A Phase 3 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 516
- Enrollment target
NCT03517722 is a Phase 3 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 516 participants.
The verdict
NCT03517722, a Phase 3 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 516 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard of care treatments.
Interventions
- DRUG Placebo
- DRUG Ustekinumab 90 mg
- DRUG Ustekinumab (approximately 6 mg/kg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 516 participants |
| Start Date | 2018-04-16 |
| Est. Completion | 2020-11-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03517722
The ClinicalTrials.gov registry entry for NCT03517722 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 516 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03517722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03517722 about?
NCT03517722 is a clinical study titled "A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus". The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard of care treatments.
What is the current status of trial NCT03517722?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 516 participants. The study started on 2018-04-16. Estimated completion is 2020-11-05.
What interventions are being tested in trial NCT03517722?
The interventions under investigation include: Placebo (DRUG), Ustekinumab 90 mg (DRUG), Ustekinumab (approximately 6 mg/kg) (DRUG).
Who is sponsoring clinical trial NCT03517722?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.